This latest regulatory milestone underscores the breadth and depth of clinical data on olaparib, and not only demonstrates its efficacy as maintenance therapy, but adds to the data presented earlier this year showing sustained quality of life for patients undergoing treatment for this serious disease." AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) closed up 8.79% on Monday at $3.34 with over 6.8 million shares traded on the day and was also up slightly in afterhours trading on Monday as well. AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases.